

Erythromelalgia Survey 2021





Survey Process

> Survey format: conducted 100% online . . . PC, tablet, smartphone . . .



> Dates the survey portal was available for participation:

January 4, 2021 to January 22, 2021

2021 JANUARY						
SUN	MON	TUE	WED	THU	FRI 1	2
3	4	5				5
3			6	V	8	
0	0	(E)	B	4	6	6
7	8	B	4	3	4	23
24	25	26	27	28	29	30
31		1		1	+	+

- > Survey reach:
 - Survey description and link to the survey questions were made available and seen as follows:

Emails sent directly to all TEA registered members	3,300 emails sent	1,066 opened
Posts shared on TEA Facebook page	3,642 followers	reached 596 individuals
Posts shared on Fans of TEA Facebook page	247 followers	reached 37 individuals




Survey Process

The numbers:					
Total estimated # of people the survey was sent to:	7,189				
Total estimated # of people that opened the survey announcement:	1,699	23.6% of total survey announcements sent			
Total # of people that completed and returned the survey:	683	40% of total survey announcements opened and read by recipients			



Respondent Demographics



				Grand
Age at time of survey:	Female	Male	Other	Total
0 - 17 years	4	2	1	7
18-35 years	45	6	2	54
36-50 years	93	16	1	110
50-65 years	193	32	0	225
> 65 years	224	61	0	285


Note: Females are more likely to respond to surveys which can skew the results





Respondent Demographics

Ethnicity:



- Other
- Black or African American
- American Indian or Alaska Native
- White


- Native Hawaiian or Other Pacific Islander
- Asian
- Hispanic or Latinx






Diagnosis Data

Survey participants' diagnosis process:




Provider that made diagnosis:





Diagnosis Data

Length of time to get a diagnosis of EM:



Why the delay in diagnosis:	# of respondents
Provider unfamiliar with EM	479
Initially misdiagnosed	171
Mild symptoms	103
Live far from specialist	46
Insurance Barriers	18





Diagnosis Data

Genetic testing to confirm EM diagnosis:

	# of
	participants
No	531
Unsure	122
Yes	30

For those that responded 'Yes' – this is the breakdown of the gene specified:

```
Nav1.7 (no other specifics)
                                            4
 Nav1.7 (with further specifics):
   SCN9A
   L858H
   SCN10A/SCN9A
   SCN11A
   JAK2 (Polycythemia Vera)
                                          11
Total Nav1.7
Don't know
                                          14
No related genetic mutation found
Total
                                          30
```

Related question . . . 'Do you have any relatives that have been diagnosed with EM?'



521:

✓ Not Sure **121**;

✓ Yes **41**




Other Diagnoses

Most reported comorbidities of survey respondents:


Disease or condition reported Raynauds 42 **Fibromyalgia** 39 **Small Fiber Neuropathy** 24 **Unspecified autoimmune disorders** 20 **Diabetes** 16 Hashimoto's disease 16 14 Lupus Migraines 14 Dysautonomia Rosacea Polycythemia Vera Lyme **Multiple Sclerosis**



Was there a specific event that triggered the first EM symptoms?




Triggering events or conditions reported:





Age at symptom onset:

% of respondents for each age group:



of respondents for each age group:


Under 18 years	63
18-24 years	37
25-34 years	80
35-50 years	194
51- 64 years	208
65+ years	98
Don't know	3
Grand Total	683






Location(s) on the body of EM flares:

The following shows the number of participants who have flaring in **at least one** of the following areas:




Flaring occurs in **multiple locations** in the majority of survey participants:





Depth of pain during EM flaring:




Pain changes over time (since first becoming aware of symptoms):

# of	
espondents	


	Now About the Same	102
Fluctuated	Now Better	114
	Now Worse	103
	Stayed about the same	97
Steady	Steadily better	40
	Steadily worse	214
Not s	13	



Percentage reporting each of these pain descriptions:



Additional pain descriptions (percentage reporting having one or more of these symptoms during EM flare):




Many people reported multiple characteristics of pain





Frequency of EM flare-ups


(also known as 'flaring'):



of respondents for each level of frequency


How long do the flares last?

For those who get flaring every day:




of survey participants reporting

For those who get flaring some days:




of survey participants reporting

For those who get flaring most days:



of survey participants reporting


For those who get flaring almost never:




of survey participants reporting



Typical daily EM Pain:



Worst case EM Pain:




^{*0 =} no pain and 10 = most severe pain






Survey respondents reported their level of sweating:

During EM flares:




Not in a flare:






How much does the pain of EM interfere with your <u>daily life</u>?



Very similar results for the question: How much does EM pain interfere with your enjoyment of life?




PERCENT REPORTING AT EACH LEVEL OF INTERFERENCE

Scale: 0 = no interference with daily life and 10 = completely interferes with daily life






Percent of survey participants reporting these aspects of life have been negatively affected by EM symptoms:






Percent of survey participants reporting these factors trigger their EM symptoms:






Overall level of control reported over EM flares/attacks:






Survey takers were asked what level of control do they have over EM flares through:


> Lifestyle changes:




> Cooling:



> Resting and elevating effected areas:



> Resting and elevating effected areas:





Treatment data

Medications most reported as tried or currently using (and the affect on symptoms):

Of those who reported using the medication, below details the level of improvement of symptoms (if any) from the drug

				-			
MEDICATION NAME	Medication Class	Total # who tried this drug	A Lot	Some	Little	None	Worsened
Aspirin	NSAID	67	6	9	3	49	
Gabapentin (Neurontin)	Anticonvulsant and nerve pain medication	34	3	7		24	
Pregabalin (Lyrica)	Nerve pain	19	1	2	1	14	1
Duloxetine (Cymbalta)	Antidepressant and nerve pain medication	13		1	1	8	3
Venlafaxine (Effexor)*	Antidepressant and nerve pain medication	8	1	3	1	2	1
Amytriptyline (Elavil, Endep)	Tricyclic antidepressant	7		1	1	5	
Mexiletine	Antiarrhythmic	5	1			4	
Amlodipine (Norvasc)	Calcium Channel Blocker	6		3		1	2
Nifidepine	Calcium Channel Blocker	4		1		2	1

^{*}also known as a serotonin-norepinephine reuptake inhibitor (SNRI)

Take-away: The medication most attempted is aspirin with 73% reporting no improvement and 22% reporting at least some improvement. The overall majority of the respondents (75%) had little to no improvement (or worsening) of EM symptoms from the medications attempted.



Treatment data

Other medications reported as tried or currently using (and the affect on symptoms):

Take-away: A wide array of medicines have been tried by the EM population with very limited success in reducing the pain and discomfort of the symptoms.

				: 		; 1 1 1 1 1 1 1 1 1	Total # Respondents that tried the
Medication Name	Medication Class	A Lot	Some	Little	None	Worsened	medication
		!		!	!	!	
Midrodine	Alpha-adrenergic agonists	!		!	1		1
		:		<u>:</u>	İ	_	_
Carbamazepine	Anticonvulsant and nerve pain medication	: !	İ	i !		2	2
Clonazepam (Klonopin)	Anticonvulsant and anxiety	! !		! !	2	!	2
Carbamazepine (Tegretol)	Anticonvulsant and nerve pain medication	 		! ! ! !	1		1
Topiramate (Topamax)**	Anticonvulsant and nerve pain medication	! !		 - -	 	1	1
Clopidogrel	Antiplatelet drug	:	i	:	1	1	1
Bisoprolol	Beta blocker			:	1		1
Labetalol	Beta blocker		1			1	1
Propranolol	Beta blocker	<u> </u>		! !	2	1	3
Adalat XL	Calcium Channel Blocker	! !	-	! !		2	2
Diltiazem (Cardizem)	Calcium Channel Blocker	1		! !	-	! !	1
Clonidine	Sedative and Antihypertensive	! !	-	! ! !	1	1 1 1	1
Isotretinoin (Accutane)	cystic acne	:		1	:	!	1
Maxide	Diuretic	:	1	! !			1
Pentoxifilline	Hemorrheologic agents*	! !		! !	1	!	1
Progesterone (Prometrium)	Hormone	:		1	:		1
Morphine	Narcotic	:		:	1	1	1
Oxycodone	Narcotic	:	1	!	1	!	1
Tramadol	Narcotic	1			1	1	2
Ibuprofrn	NSAID	!	2		İ	İ	2
Indomenthicin	NSAID		1	!	i !		1
Hydrocodone (Vicodin)	Opiod	1	1	<u> </u>	i	i	2
Other Opioids	Opiod			2	1		3
Antihistamines	OTC antihistamines		3		3	i	6
Cetirizine (Zyrtec)	OTC antihistamines				1		1
Acetaminophen	OTC pain reliever				1		1
Desloratidine	Prescription antihistamine			1			1
Rupatadine	Prescription antihistamine	!		!	1	!	1
Fluoxetine (Prozac)	SSRI	! !	1	! !	1	!	2
Escitalopram (Lexapro)	SSRI	:		!	2	!	2
Prednisone	Steroid	1		!	2	!	3
Desipramine	Tricyclic antidepressant	1	1		1	1	1



Alternative treatments data

A sample of other alternative treatments reported:*

		No effect
	Improved	on
	symptorms	symptoms
Acupuncture	17	108
Biofeedback	3	1
CBD	7	13
Compression stockings	5	0
Lidocaine	5	3
Marijuana	3	5
Meditation	5	4
Nerve block	1	7
THC	4	2

^{*}There were numerous other items listed that one or two participants reported having tried that are not listed in this document such as homeopathic tinctures, Epsom salts, Botox and TENS unit.